JP2023536437A5 - - Google Patents

Info

Publication number
JP2023536437A5
JP2023536437A5 JP2023504833A JP2023504833A JP2023536437A5 JP 2023536437 A5 JP2023536437 A5 JP 2023536437A5 JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023504833 A JP2023504833 A JP 2023504833A JP 2023536437 A5 JP2023536437 A5 JP 2023536437A5
Authority
JP
Japan
Prior art keywords
disease
erap2
mhc
hla
inhibitor according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/043062 external-priority patent/WO2022026336A1/en
Publication of JP2023536437A publication Critical patent/JP2023536437A/ja
Publication of JP2023536437A5 publication Critical patent/JP2023536437A5/ja
Pending legal-status Critical Current

Links

JP2023504833A 2020-07-25 2021-07-23 小胞体アミノペプチダーゼ2(erap2)媒介性免疫応答の調節 Pending JP2023536437A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063056562P 2020-07-25 2020-07-25
US63/056,562 2020-07-25
US202163171672P 2021-04-07 2021-04-07
US63/171,672 2021-04-07
PCT/US2021/043062 WO2022026336A1 (en) 2020-07-25 2021-07-23 Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Publications (2)

Publication Number Publication Date
JP2023536437A JP2023536437A (ja) 2023-08-25
JP2023536437A5 true JP2023536437A5 (cg-RX-API-DMAC7.html) 2024-07-30

Family

ID=77564145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504833A Pending JP2023536437A (ja) 2020-07-25 2021-07-23 小胞体アミノペプチダーゼ2(erap2)媒介性免疫応答の調節

Country Status (10)

Country Link
US (1) US12662539B2 (cg-RX-API-DMAC7.html)
EP (1) EP4188963A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023536437A (cg-RX-API-DMAC7.html)
KR (1) KR20230043888A (cg-RX-API-DMAC7.html)
CN (1) CN116194484A (cg-RX-API-DMAC7.html)
AU (1) AU2021316196B2 (cg-RX-API-DMAC7.html)
CA (1) CA3189755A1 (cg-RX-API-DMAC7.html)
IL (1) IL299986A (cg-RX-API-DMAC7.html)
MX (1) MX2023001059A (cg-RX-API-DMAC7.html)
WO (1) WO2022026336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189755A1 (en) 2020-07-25 2022-02-03 Regeneron Pharmaceuticals, Inc. Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response
WO2023064850A1 (en) * 2021-10-14 2023-04-20 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
US12613286B2 (en) 2024-01-22 2026-04-28 Garrett Transportation I Inc. System and method for battery parameter recharacterization
US12704384B2 (en) 2024-05-28 2026-08-11 Garrett Transportation 1 Inc. Range estimation for battery electric vehicles
CN118593462B (zh) * 2024-06-28 2026-01-27 沈阳药科大学 鼠尾草酸作为erap1的抑制剂在制备治疗强直性脊柱炎药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005269B2 (en) 2002-06-06 2006-02-28 The Regents Of The University Of California ERAAP modulators regulate immune responses
WO2012009547A2 (en) 2010-07-14 2012-01-19 The Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
WO2012047294A2 (en) 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
US8969254B2 (en) 2010-12-16 2015-03-03 Dana-Farber Cancer Institute, Inc. Oligonucleotide array for tissue typing
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗-hla-b*27抗體及其用途
ES2762403T3 (es) 2012-04-26 2020-05-25 Stichting Vumc Biomarcadores
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
KR101748867B1 (ko) 2013-04-19 2017-06-20 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 자동화 시스템
EP3489369B1 (en) 2013-06-25 2020-10-28 Turun yliopisto Method of predicting risk for type 1 diabetes
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
US10927412B2 (en) 2013-10-01 2021-02-23 The Regents Of The University Of California Endometriosis classifier
US10166210B2 (en) 2014-06-12 2019-01-01 Nsabp Foundation, Inc. Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
GB201609712D0 (en) 2016-06-03 2016-07-20 Babraham Inst Disease targets and biomarkers
US20190375842A1 (en) 2018-01-04 2019-12-12 Vanderbilt University Check point inhibition in organ fibrosis
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US11632728B2 (en) 2019-07-18 2023-04-18 Qualcomm Incorporated Directional measurements for sidelink synchronization signal transmission
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
WO2021113805A1 (en) 2019-12-05 2021-06-10 The General Hospital Corporation Multi-biomarker prediction models for multiple infection episodes following blunt trauma
CA3189755A1 (en) 2020-07-25 2022-02-03 Regeneron Pharmaceuticals, Inc. Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Similar Documents

Publication Publication Date Title
KR102622309B1 (ko) 염색체 상호작용의 검출
Merkel et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody–associated vasculitis
Stone et al. IgG4-related disease
Puthia et al. IRF7 inhibition prevents destructive innate immunity—A target for nonantibiotic therapy of bacterial infections
CA2846307C (en) Method for diagnosing a neurodegenerative disease
US12188081B2 (en) Bioinformatics methods of in silico validation and selection of circRNAs
EP3538891A2 (en) Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells
Frade et al. Polymorphism in the alpha cardiac muscle actin 1 gene is associated to susceptibility to chronic inflammatory cardiomyopathy
Abe‐Hatano et al. Whole genome sequencing of 45 Japanese patients with intellectual disability
Lim et al. Exome sequencing identifies KIAA1377 and C5orf42 as susceptibility genes for monomelic amyotrophy
Maroilley et al. Immunome differences between porcine ileal and jejunal Peyer’s patches revealed by global transcriptome sequencing of gut-associated lymphoid tissues
Turkunova et al. Molecular genetics and pathogenesis of the floating harbor syndrome: case report of long-term growth hormone treatment and a literature review
CN116194484A (zh) 内质网氨肽酶2(erap2)介导的免疫应答的调节
Hsu et al. Effect of resistance training on satellite cells in old mice–a transcriptome study: Implications for sarcopenia
Schramm et al. Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates
EP3013976B1 (en) Method of predicting risk for type 1 diabetes before seroconversion
Milazzo et al. UBE3A reinstatement restores behaviorand proteome in an Angelman syndrome mouse model of imprinting defects
JP2024515240A5 (cg-RX-API-DMAC7.html)
Gardet et al. Pristane-accelerated autoimmune disease in (SWR X NZB) F1 mice leads to prominent tubulointerstitial inflammation and human lupus nephritis-like fibrosis
JP2024521754A5 (cg-RX-API-DMAC7.html)
Ismail Bioinformatics of Autoimmune Diseases
ES2656587B1 (es) Método para predecir la respuesta clínica a un tratamiento con agentes antiinflamatorios
Zhang et al. Associations of 2,922 genetically predicted plasma protein levels with mental illness and response to treatment
Xiao et al. HCV F protein amplifies the predictions of IL-28B and CTLA-4 polymorphisms about the susceptibility and outcomes of HCV infection in Southeast China
Meijer et al. A primed immune transcriptional program is activated in oligodendroglia in multiple sclerosis